National Kidney Foundation Spring Clinical Meetings 2026 Newsroom

“IgA nephropathy remains an area of high unmet need, and many patients continue to progress despite currently available therapies. At Vertex, we are committed to addressing the underlying immune drivers of IgAN and delivering meaningful outcomes for patients living with this chronic, progressive disease. We strive to meet the IgAN community where they are, from listening to lived experiences that may evolve how we treat and measure disease, to helping patients and care teams better understand the markers that matter most, including proteinuria – we aim to help people navigate IgAN with greater clarity and work toward a future that isn’t solely defined by kidney decline.”

“Renal medicine has entered a new era defined by momentum and hope for patients. Our teams at Vertex are excited to be at the leading edge of an incredible wave of research and development, working hard each day to ensure people living with serious kidney diseases, including IgAN, can benefit from innovations in care and potentially transformative therapies on the horizon.”

“There is real progress underway in kidney medicine and a growing sense that we can rethink how serious kidney diseases are approached, studied, and treated. At Vertex, we are proud to be advancing a novel approach to IgAN treatment – harnessing our deep understanding of causal human biology to target disease progression and potentially redefine the patient experience."

“IgAN remains a serious and progressive kidney disease that can have a profound impact on patients’ lives. At Vertex, our goal is to bring forward therapies that can meaningfully improve outcomes for people living with IgAN. At this year’s National Kidney Foundation Spring Clinical Meetings, we look forward to deepening our understanding of patient and physician needs in the diagnosis and management of IgAN. We are also proud to share real-world insights on IgAN treatment patterns and the importance of disease markers such as proteinuria in guiding care.”

“Breakthroughs for people living with kidney diseases are only possible when patient voices and lived experiences are actively guiding our work – and real-world evidence plays a crucial role in how we understand and address diseases like IgAN. As insights into disease markers continue to shape clinical guidance, our focus is on working alongside patients to truly understand what they need and embed those insights from the start.”